<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01994538</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-008-13S</org_study_id>
    <secondary_id>I01BX007080</secondary_id>
    <nct_id>NCT01994538</nct_id>
  </id_info>
  <brief_title>Seven vs. 14 Days Treatment for Male Urinary Tract Infection</brief_title>
  <official_title>Seven Versus Fourteen Day Treatment for Male Urinary Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the treatment of urinary tract infection in men. Specifically,&#xD;
      the investigators are looking to see if shorter duration of antibiotics (7 days) is any worse&#xD;
      than longer duration of antibiotics (14 days). The investigators will also study whether&#xD;
      longer treatment leads to an increase in antibiotic resistant bacteria in the large intestine&#xD;
      (colon), or an increase in drug side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a randomized placebo-controlled trial of treatment duration for male&#xD;
      urinary tract infection (UTI). Specifically, 319 men with a UTI will be randomized to 7 vs.&#xD;
      14 days of antimicrobial treatment. The primary outcome is resolution of UTI symptoms,&#xD;
      assessed 14 days after completing active antimicrobial treatment. Secondary outcomes include&#xD;
      recurrent UTI in the 4 weeks after treatment, adverse drug events, and intestinal carriage of&#xD;
      antimicrobial resistant Gram-negative bacilli. Subjects will be enrolled from the Primary&#xD;
      Care Clinic and Emergency Department at the Minneapolis VA Medical Center (MVAMC).&#xD;
&#xD;
      Currently, the optimal treatment duration for male UTI is unknown. A clinical trial of 14 vs.&#xD;
      28 days of treatment showed no difference in outcomes, whereas another trial of 3 vs.14 days&#xD;
      showed an increase in recurrence with 3 days of treatment. However, current treatment&#xD;
      recommendations are to treat men with UTI for 7 to 14 days, and no data exist to favor the&#xD;
      shorter or longer duration. Most men with UTI in the VA are treated for more than 7 days,&#xD;
      which is associated with a small but significant increase in Clostridium difficile infection.&#xD;
      Additionally, other studies of non-UTI infectious diseases have shown that longer-duration&#xD;
      treatment leads to increased antimicrobial resistance. Longer-duration treatment is also more&#xD;
      costly and inconvenient to patients. Thus, since longer-duration treatment is associated with&#xD;
      some adverse outcomes, in order to justify longer-duration treatment thee must be some&#xD;
      clinically significant benefit to the extended treatment.&#xD;
&#xD;
      Accordingly, the proposed randomized placebo-controlled trial of 319 men with UTI will test&#xD;
      the hypothesis that 7 days of antimicrobial treatment is non-inferior for the resolution of&#xD;
      UTI symptoms when compared to 14 days of treatment. This study will provide valuable&#xD;
      information to VA patients and clinicians regarding a common and understudied clinical&#xD;
      decision.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2014</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of UTI Symptoms 14 Days After Completing Active Antimicrobial Therapy</measure>
    <time_frame>14 days</time_frame>
    <description>This outcome will be assessed in a binary manner. Subjects with persistent UTI symptoms or having received further antimicrobials because of UTI symptoms will be considered to have not met the primary outcome, whereas those without persistent UTI symptoms and not having received further antimicrobials will be considered to have met the primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent UTI Within 28 Days of Completing Active Study Medication</measure>
    <time_frame>28 days</time_frame>
    <description>New onset of symptomatic UTI within the 28 day follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Event in the 28 Days After Completing Study Medication</measure>
    <time_frame>28 days</time_frame>
    <description>The incidence of adverse drug events, including nausea, vomiting, diarrhea, dizziness, headache, drug allergy, and C. difficile infection, both individually and in aggregate, will be compared between treatment groups&#xD;
This outcome is number of subjects experiencing ANY adverse drug event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal Carriage of Antimicrobial-resistant Gram Negative Bacilli</measure>
    <time_frame>7 days</time_frame>
    <description>Intestinal carriage of antimicrobial-resistant Gram-negative bacilli after completing study medication, as compared to a baseline sample taken early in treatment. Antimicrobial resistance for this measure was defined as newly detected resistance to either of the study drugs, ciprofloxacin or trimethoprim/sulfamethoxazole.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">273</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Longer (14 day) duration antimicrobial treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>14 days of ciprofloxacin or trimethoprim/sulfamethoxazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shorter (7 day) duration antimicrobial treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Longer therapy duration</intervention_name>
    <description>14 days of antimicrobial treatment</description>
    <arm_group_label>Longer (14 day) duration antimicrobial treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Shorter therapy duration</intervention_name>
    <description>7 days of antimicrobial treatment</description>
    <arm_group_label>Shorter (7 day) duration antimicrobial treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Must have all&#xD;
&#xD;
          -  Male gender&#xD;
&#xD;
          -  New-onset (within 7 days) of at least one of the following symptoms/findings: dysuria,&#xD;
             urinary frequency, urgency, hematuria, perineal pain, supra-pubic pain, costovertebral&#xD;
             angle tenderness, or flank pain&#xD;
&#xD;
          -  Treated as an outpatient (Primary Care Center or Emergency Department), with &lt; 24&#xD;
             hours observation in the hospital or Emergency Department following the time of&#xD;
             initial diagnosis&#xD;
&#xD;
          -  Prescribed treatment with at least 7 days, but not more than 14 days, of either&#xD;
             ciprofloxacin or TMP-SMZ&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Must have none&#xD;
&#xD;
          -  Admission to the hospital (for &gt; 24h) at the time of diagnosis&#xD;
&#xD;
          -  Documented fever at time of initial evaluation ( 38.0 Celsius)&#xD;
&#xD;
          -  Previous enrollment in the study&#xD;
&#xD;
          -  Treatment for UTI in past 14 days&#xD;
&#xD;
          -  Not able to give informed consent&#xD;
&#xD;
          -  Unwilling to return for study visit&#xD;
&#xD;
          -  Symptoms thought more likely to be caused by a non-UTI diagnosis (e.g., urinary&#xD;
             calculus, sexually transmitted infection, etc.)&#xD;
&#xD;
          -  Other antimicrobial therapy (new or ongoing) prescribed for a non-UTI diagnosis (e.g.,&#xD;
             cellulitis, pneumonia, etc.)&#xD;
&#xD;
          -  Treatment initiated with an empiric antimicrobial to which the organism isolated in&#xD;
             the urine culture is non-susceptible based on standard laboratory criteria&#xD;
&#xD;
          -  Treatment initiated with an empiric antimicrobial regimen that is underdosed, based on&#xD;
             current guidelines and reviews&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Study of UTI in men</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitri M Drekonja, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis VA Health Care System, Minneapolis, MN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minneapolis VA Health Care System, Minneapolis, MN</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center, Houston, TX</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>November 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <results_first_submitted>October 2, 2020</results_first_submitted>
  <results_first_submitted_qc>October 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 28, 2020</results_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Tract Infections</keyword>
  <keyword>Urinary antiinfective agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>No formal plan submitted at time of grant. Will handle such requests on a case-by-case basis with input from local privacy officer and institutional review board.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Anticipate will share data for 2 years after publication of the primary result manuscript</ipd_time_frame>
    <ipd_access_criteria>Requests will be handled on a case-by-case basis with input from the local privacy officer and IRB.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT01994538/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrolled subjects are afebrile men with symptomatic urinary tract infection who were initially treated with 7-14 days of trimethoprim/sulfamethoxazole (TMP/SMZ) or ciprofloxacin by the treating clinician. Subjects were randomized prior to day 8 of treatment to an additional 7 days of their original study drug (14d group) or placebo (7d group.</recruitment_details>
      <pre_assignment_details>Primary analysis was per-protocol, and included all subjects who took at least 26 of 28 doses of medication.&#xD;
Intention to treat analysis includes all randomized subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Longer (14 Day) Duration Antimicrobial Treatment</title>
          <description>14 days of ciprofloxacin or trimethoprim/sulfamethoxazole&#xD;
Longer therapy duration: 14 days of antimicrobial treatment</description>
        </group>
        <group group_id="P2">
          <title>Shorter (7 Day) Duration Antimicrobial Treatment</title>
          <description>7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo&#xD;
Shorter therapy duration: 7 days of antimicrobial treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Longer (14 Day) Duration Antimicrobial Treatment</title>
          <description>14 days of ciprofloxacin or trimethoprim/sulfamethoxazole&#xD;
Longer therapy duration: 14 days of antimicrobial treatment</description>
        </group>
        <group group_id="B2">
          <title>Shorter (7 Day) Duration Antimicrobial Treatment</title>
          <description>7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo&#xD;
Shorter therapy duration: 7 days of antimicrobial treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="136"/>
            <count group_id="B2" value="136"/>
            <count group_id="B3" value="272"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.8" spread="11.6"/>
                    <measurement group_id="B2" value="67.8" spread="11.6"/>
                    <measurement group_id="B3" value="67.8" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indwelling catheter use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intermittent catheter use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CKD</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cerebrovascular accident</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spinal cord injury</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostatic hypertrophy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostatitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate Cancer</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior UTI</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Incontinence</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urethral stricture</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Resolution of UTI Symptoms 14 Days After Completing Active Antimicrobial Therapy</title>
        <description>This outcome will be assessed in a binary manner. Subjects with persistent UTI symptoms or having received further antimicrobials because of UTI symptoms will be considered to have not met the primary outcome, whereas those without persistent UTI symptoms and not having received further antimicrobials will be considered to have met the primary outcome.</description>
        <time_frame>14 days</time_frame>
        <population>Per-protocol analysis (including all subjects who took medication as directed, defined as at least 26 of 28 doses, missing no more than 2 consecutive doses)</population>
        <group_list>
          <group group_id="O1">
            <title>Longer (14 Day) Duration Antimicrobial Treatment</title>
            <description>14 days of ciprofloxacin or trimethoprim/sulfamethoxazole&#xD;
Longer therapy duration: 14 days of antimicrobial treatment</description>
          </group>
          <group group_id="O2">
            <title>Shorter (7 Day) Duration Antimicrobial Treatment</title>
            <description>7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo&#xD;
Shorter therapy duration: 7 days of antimicrobial treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Resolution of UTI Symptoms 14 Days After Completing Active Antimicrobial Therapy</title>
          <description>This outcome will be assessed in a binary manner. Subjects with persistent UTI symptoms or having received further antimicrobials because of UTI symptoms will be considered to have not met the primary outcome, whereas those without persistent UTI symptoms and not having received further antimicrobials will be considered to have met the primary outcome.</description>
          <population>Per-protocol analysis (including all subjects who took medication as directed, defined as at least 26 of 28 doses, missing no more than 2 consecutive doses)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent UTI Within 28 Days of Completing Active Study Medication</title>
        <description>New onset of symptomatic UTI within the 28 day follow-up period</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Longer (14 Day) Duration Antimicrobial Treatment</title>
            <description>14 days of ciprofloxacin or trimethoprim/sulfamethoxazole&#xD;
Longer therapy duration: 14 days of antimicrobial treatment</description>
          </group>
          <group group_id="O2">
            <title>Shorter (7 Day) Duration Antimicrobial Treatment</title>
            <description>7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo&#xD;
Shorter therapy duration: 7 days of antimicrobial treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent UTI Within 28 Days of Completing Active Study Medication</title>
          <description>New onset of symptomatic UTI within the 28 day follow-up period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Drug Event in the 28 Days After Completing Study Medication</title>
        <description>The incidence of adverse drug events, including nausea, vomiting, diarrhea, dizziness, headache, drug allergy, and C. difficile infection, both individually and in aggregate, will be compared between treatment groups&#xD;
This outcome is number of subjects experiencing ANY adverse drug event</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Longer (14 Day) Duration Antimicrobial Treatment</title>
            <description>14 days of ciprofloxacin or trimethoprim/sulfamethoxazole&#xD;
Longer therapy duration: 14 days of antimicrobial treatment</description>
          </group>
          <group group_id="O2">
            <title>Shorter (7 Day) Duration Antimicrobial Treatment</title>
            <description>7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo&#xD;
Shorter therapy duration: 7 days of antimicrobial treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Drug Event in the 28 Days After Completing Study Medication</title>
          <description>The incidence of adverse drug events, including nausea, vomiting, diarrhea, dizziness, headache, drug allergy, and C. difficile infection, both individually and in aggregate, will be compared between treatment groups&#xD;
This outcome is number of subjects experiencing ANY adverse drug event</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intestinal Carriage of Antimicrobial-resistant Gram Negative Bacilli</title>
        <description>Intestinal carriage of antimicrobial-resistant Gram-negative bacilli after completing study medication, as compared to a baseline sample taken early in treatment. Antimicrobial resistance for this measure was defined as newly detected resistance to either of the study drugs, ciprofloxacin or trimethoprim/sulfamethoxazole.</description>
        <time_frame>7 days</time_frame>
        <population>of the 163 subjects who participated in the optional intestinal carriage sub-study, 65 had growth in both of the submitted stool samples and are included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Longer (14 Day) Duration Antimicrobial Treatment</title>
            <description>14 days of ciprofloxacin or trimethoprim/sulfamethoxazole&#xD;
Longer therapy duration: 14 days of antimicrobial treatment</description>
          </group>
          <group group_id="O2">
            <title>Shorter (7 Day) Duration Antimicrobial Treatment</title>
            <description>7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo&#xD;
Shorter therapy duration: 7 days of antimicrobial treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Intestinal Carriage of Antimicrobial-resistant Gram Negative Bacilli</title>
          <description>Intestinal carriage of antimicrobial-resistant Gram-negative bacilli after completing study medication, as compared to a baseline sample taken early in treatment. Antimicrobial resistance for this measure was defined as newly detected resistance to either of the study drugs, ciprofloxacin or trimethoprim/sulfamethoxazole.</description>
          <population>of the 163 subjects who participated in the optional intestinal carriage sub-study, 65 had growth in both of the submitted stool samples and are included in this analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Longer (14 Day) Duration Antimicrobial Treatment</title>
          <description>14 days of ciprofloxacin or trimethoprim/sulfamethoxazole&#xD;
Longer therapy duration: 14 days of antimicrobial treatment</description>
        </group>
        <group group_id="E2">
          <title>Shorter (7 Day) Duration Antimicrobial Treatment</title>
          <description>7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo&#xD;
Shorter therapy duration: 7 days of antimicrobial treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any adverse event</sub_title>
                <description>Adverse events assessed were: C difficile, nausea, vomiting, diarrhea, dizziness, headache, allergic reaction, thrush, muscle/joint aches, abnormal blood sugars, and changes in warfarin dosing. Subjects may have more than one adverse event.</description>
                <counts group_id="E1" events="51" subjects_affected="33" subjects_at_risk="136"/>
                <counts group_id="E2" events="40" subjects_affected="28" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Goal enrollment was 290; actual enrollment of 273 slightly reduces power to detect minimally clinically significant difference.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dimitri Drekonja, MD, MS</name_or_title>
      <organization>Minneapolis VA Health Care System</organization>
      <phone>612 467 4183</phone>
      <email>dimitri.drekonja@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

